[go: up one dir, main page]

EA201501166A1 - Соединение гликозаминогликана, способ его получения и применение - Google Patents

Соединение гликозаминогликана, способ его получения и применение

Info

Publication number
EA201501166A1
EA201501166A1 EA201501166A EA201501166A EA201501166A1 EA 201501166 A1 EA201501166 A1 EA 201501166A1 EA 201501166 A EA201501166 A EA 201501166A EA 201501166 A EA201501166 A EA 201501166A EA 201501166 A1 EA201501166 A1 EA 201501166A1
Authority
EA
Eurasian Patent Office
Prior art keywords
drug
compound
glican
glycosamino
preparation
Prior art date
Application number
EA201501166A
Other languages
English (en)
Other versions
EA031285B1 (ru
Inventor
Хуа-Ян Линь
Original Assignee
Айхол Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Айхол Корпорейшн filed Critical Айхол Корпорейшн
Publication of EA201501166A1 publication Critical patent/EA201501166A1/ru
Publication of EA031285B1 publication Critical patent/EA031285B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение относится к соединению, образующему конъюгат лекарственного препарата с гликозаминогликаном, например гиалуроновой кислотой (НА), в котором лекарственный препарат пригоден для лечения заболеваний, как например, воспаления, аутоиммунного заболевания, аллергии, инфекции и предпочтительно рака. Конъюгированное соединение данного изобретения может увеличить концентрацию лекарственного препарата в конкретном очаге болезни путем взаимодействия гликозаминогликана, используемого в качестве носителя целенаправленной доставки лекарственного препарата, и рецептора клеточной поверхности CD44, затем привести к улучшению терапевтической эффективности и снижению системного побочного действия доставляемого в очаг лекарственного препарата.
EA201501166A 2013-08-29 2014-08-27 Конъюгат гиалуроновой кислоты и стероида, способ его получения и применение EA031285B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361871352P 2013-08-29 2013-08-29
PCT/US2014/052813 WO2015031425A1 (en) 2013-08-29 2014-08-27 Compound of glycosaminoglycan and its preparation method as well as application

Publications (2)

Publication Number Publication Date
EA201501166A1 true EA201501166A1 (ru) 2016-10-31
EA031285B1 EA031285B1 (ru) 2018-12-28

Family

ID=52584073

Family Applications (4)

Application Number Title Priority Date Filing Date
EA201992517A EA038278B1 (ru) 2013-08-29 2014-06-27 Конъюгат гиалуроновой кислоты и леналидомида, способ его получения и применение для лечения рака
EA201690487A EA034600B1 (ru) 2013-08-29 2014-06-27 Конъюгаты гиалуроновой кислоты с антагонистами cox-2 и их применение для лечения рака
EA201992518A EA038422B1 (ru) 2013-08-29 2014-06-27 Конъюгат гиалуроновой кислоты и гемцитабина, способ его получения и применение для лечения рака
EA201501166A EA031285B1 (ru) 2013-08-29 2014-08-27 Конъюгат гиалуроновой кислоты и стероида, способ его получения и применение

Family Applications Before (3)

Application Number Title Priority Date Filing Date
EA201992517A EA038278B1 (ru) 2013-08-29 2014-06-27 Конъюгат гиалуроновой кислоты и леналидомида, способ его получения и применение для лечения рака
EA201690487A EA034600B1 (ru) 2013-08-29 2014-06-27 Конъюгаты гиалуроновой кислоты с антагонистами cox-2 и их применение для лечения рака
EA201992518A EA038422B1 (ru) 2013-08-29 2014-06-27 Конъюгат гиалуроновой кислоты и гемцитабина, способ его получения и применение для лечения рака

Country Status (18)

Country Link
US (7) US9572832B2 (ru)
EP (2) EP3038656B1 (ru)
JP (2) JP6404925B2 (ru)
KR (2) KR102283978B1 (ru)
CN (5) CN113893354A (ru)
AU (6) AU2014314536B2 (ru)
BR (2) BR112016004357B1 (ru)
CA (3) CA3133859C (ru)
DK (1) DK3038656T3 (ru)
EA (4) EA038278B1 (ru)
ES (2) ES2893329T3 (ru)
HU (1) HUE056434T2 (ru)
LT (1) LT3038656T (ru)
MY (1) MY180502A (ru)
PL (1) PL3038656T3 (ru)
PT (1) PT3038656T (ru)
TW (2) TWI526212B (ru)
WO (2) WO2015028172A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9572832B2 (en) * 2013-08-29 2017-02-21 Holy Stone Healthcare Co., Ltd. Compound of glycosaminoglycan and its fabrication method as well as application
EA027663B1 (ru) * 2016-05-20 2017-08-31 Тютор С.А.С.И.Ф.И.А. Способ получения твёрдой лекарственной формы для перорального применения и твёрдая лекарственная форма для перорального применения, полученная согласно указанному способу
US11524079B2 (en) 2019-06-03 2022-12-13 Aihol Corporation Hyaluronan conjugates and uses thereof
US11458204B2 (en) 2020-06-02 2022-10-04 Aihol Corporation Method for improving substitution rate and/or substitution efficiency of hyaluronan-drug conjugates
BR112022018529A2 (pt) * 2020-06-08 2022-12-13 Aihol Corp Usos de conjugado de hialuronano
US20220401567A1 (en) * 2021-06-18 2022-12-22 Aihol Corporation Uses of hyaluronan conjugate
CN116726186A (zh) * 2022-03-11 2023-09-12 四川省医学科学院·四川省人民医院 药物递送系统及其在制备抗黑色素瘤药物中的应用
PL442924A1 (pl) * 2022-11-23 2024-05-27 Politechnika Śląska Prolek - glikokoniugat pochodny gemcytabiny, jako związek o działaniu przeciwnowotworowym, sposób otrzymywania i zastosowanie

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8713662D0 (en) * 1987-06-11 1987-07-15 Skandigen Ab Hyaluronic acid derivatives
US5733891A (en) * 1990-10-18 1998-03-31 Shiseido Co., Ltd. Compound for medicinal ingredient and hyaluronic acid and process for producing the same
JPH0585942A (ja) * 1991-02-26 1993-04-06 Denki Kagaku Kogyo Kk インターフエロン−ヒアルロン酸及び／又はその塩の結合体
JPH0673103A (ja) * 1991-11-27 1994-03-15 Lignyte Co Ltd ヒアルロン酸高分子複合体及びその製造方法
AU5543594A (en) 1992-10-30 1994-05-24 Duke University An adhesion molecule
US5616568A (en) * 1993-11-30 1997-04-01 The Research Foundation Of State University Of New York Functionalized derivatives of hyaluronic acid
AU3085699A (en) 1998-03-13 1999-09-27 Entremed, Inc Metastatin and hyaluronate binding proteins and methods of use
KR20010025040A (ko) * 1998-05-20 2001-03-26 나가야마 오사무 관절질환 치료제 및 히알루론산의 결합체
ITPD980169A1 (it) * 1998-07-06 2000-01-06 Fidia Advanced Biopolymers Srl Ammidi dell'acido ialuronico e dei suoi derivati e processo per la loro preparazione.
GB9902412D0 (en) * 1999-02-03 1999-03-24 Fermentech Med Ltd Process
JP2001081103A (ja) * 1999-09-13 2001-03-27 Denki Kagaku Kogyo Kk ヒアルロン酸結合薬剤
JP4266571B2 (ja) * 2002-05-17 2009-05-20 生化学工業株式会社 脂質結合グリコサミノグリカンの製造法
AU2003265576A1 (en) * 2002-08-23 2004-03-11 The Mclean Hospital Corporation Corticosteroid conjugates and uses thereof
US8192744B2 (en) 2002-08-26 2012-06-05 Ibcc Holding As Drug for treating states related to the inhibition of angiogenesis and/or endothelial cell proliferation
WO2004046200A1 (ja) * 2002-11-21 2004-06-03 Chugai Seiyaku Kabushiki Kaisha 薬物徐放担体
US20060228331A1 (en) * 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
RU2390529C2 (ru) * 2004-01-07 2010-05-27 Сейкагаку Корпорейшн Производное гиалуроновой кислоты и содержащее его лекарственное средство
WO2005085294A1 (ja) * 2004-03-05 2005-09-15 Denki Kagaku Kogyo Kabushiki Kaisha ヒアルロン酸−メトトレキサート結合体
TW200612991A (en) * 2004-09-07 2006-05-01 Chugai Pharmaceutical Co Ltd Process for producing water-soluble hyaluronic acid modification
US8937052B2 (en) * 2005-07-27 2015-01-20 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
IE20060049A1 (en) * 2006-01-25 2007-08-08 Eurand Pharmaceuticals Ltd A novel drug delivery system: use of hyaluronic acid as a carrier moleclue for different classes of therapeutic active agents
WO2008134528A1 (en) * 2007-04-25 2008-11-06 Board Of Regents, The University Of Texas System Anti-cancer agent-hyaluronic acid conjugate compositions and methods
WO2009048280A2 (en) * 2007-10-09 2009-04-16 Postech Academy-Industry Foundation Long acting hyaluronic acid - peptide conjugate
US20090170195A1 (en) * 2007-12-28 2009-07-02 Kent State University Curcumin-hyaluronan compounds
KR101726715B1 (ko) * 2008-10-10 2017-04-13 폴리액티바 피티와이 리미티드 생분해성 폴리머-생물활성 모이어티 공액체
EP2360188B1 (en) * 2008-11-05 2014-09-17 National University Corporation Tokyo Medical and Dental University Hyaluronic acid derivative and pharmaceutical composition thereof
CN104861066B (zh) * 2009-03-23 2018-05-08 夸克制药公司 治疗癌症和纤维化疾病的化合物组合物和方法
US20120082717A1 (en) * 2009-06-05 2012-04-05 Snu R&Db Foundation Complex, multilayer using the same, and device coated with the multilayer
AU2010306917B2 (en) * 2009-10-13 2014-11-27 Rexahn Pharmaceuticals, Inc. Polymeric systems for the delivery of anticancer agents
US9075059B2 (en) * 2009-11-05 2015-07-07 University Of Virginia Patent Foundation Compositions and methods for detecting plectin-1 as a biomarker for cancer
CN101732728B (zh) * 2010-01-25 2012-11-14 中国药科大学 抗炎药物-多糖偶联物及其药物组合物的制备和应用
WO2011130476A2 (en) * 2010-04-16 2011-10-20 The Research Foundation Of State University Of New York Polymer-based therapeutic agents
EP2571525A4 (en) * 2010-05-18 2016-04-27 Cerulean Pharma Inc Compositions and methods for treating autoimmune and other diseases
SI2682409T1 (sl) * 2011-03-03 2017-08-31 Chugai Seiyaku Kabushiki Kaisha Derivat hialuronske kisline modificiran z amino-karboksilno kislino
ES2665254T3 (es) * 2011-07-12 2018-04-25 Holy Stone Healthcare Co., Ltd. Composiciones que comprenden ácido hialurónico para tratamiento y prevención de enfermedades relacionadas con las mucosas
JP6453214B2 (ja) * 2013-07-10 2019-01-16 生化学工業株式会社 グリコサミノグリカン誘導体及びその製造方法
US9572832B2 (en) * 2013-08-29 2017-02-21 Holy Stone Healthcare Co., Ltd. Compound of glycosaminoglycan and its fabrication method as well as application

Also Published As

Publication number Publication date
CA3133859C (en) 2023-03-14
CN114010796A (zh) 2022-02-08
AU2014311302A1 (en) 2016-01-21
CN105324132A (zh) 2016-02-10
AU2014314536A1 (en) 2016-04-07
US20240325434A1 (en) 2024-10-03
KR20160048905A (ko) 2016-05-04
US20170151336A1 (en) 2017-06-01
EA201992517A2 (ru) 2020-03-31
US20190275164A1 (en) 2019-09-12
BR112015032529B1 (pt) 2022-06-21
CA3133853A1 (en) 2015-03-05
HUE056434T2 (hu) 2022-02-28
JP2016525515A (ja) 2016-08-25
CA3133853C (en) 2023-03-07
US20150065446A1 (en) 2015-03-05
US20150065450A1 (en) 2015-03-05
US20220111062A1 (en) 2022-04-14
EA038278B1 (ru) 2021-08-04
KR101790649B1 (ko) 2017-10-26
EP3038660A4 (en) 2017-05-03
DK3038656T3 (da) 2021-10-11
US20240325435A1 (en) 2024-10-03
PT3038656T (pt) 2021-10-15
US10342878B2 (en) 2019-07-09
EA201992518A3 (ru) 2020-05-31
ES2851973T3 (es) 2021-09-09
KR102283978B1 (ko) 2021-08-02
EA038422B1 (ru) 2021-08-26
HK1225993A1 (en) 2017-09-22
NZ718048A (en) 2024-10-25
LT3038656T (lt) 2021-12-10
US9572832B2 (en) 2017-02-21
BR112016004357A2 (ru) 2017-08-01
PL3038656T3 (pl) 2022-01-10
JP6404925B2 (ja) 2018-10-17
TWI577378B (zh) 2017-04-11
EP3038660B1 (en) 2020-12-23
EA201690487A1 (ru) 2016-11-30
AU2019268085B2 (en) 2021-01-07
WO2015028172A1 (en) 2015-03-05
HK1223291A1 (en) 2017-07-28
EA031285B1 (ru) 2018-12-28
TWI526212B (zh) 2016-03-21
JP6433494B2 (ja) 2019-02-06
CN105324132B (zh) 2020-07-21
EP3038660A1 (en) 2016-07-06
BR112015032529A2 (pt) 2017-07-25
TW201509421A (zh) 2015-03-16
EA201992518A2 (ru) 2020-03-31
CA3133859A1 (en) 2015-03-05
CN105579067A (zh) 2016-05-11
AU2019268085A1 (en) 2019-12-12
KR20160014690A (ko) 2016-02-11
AU2019268087B2 (en) 2020-09-10
CN110590971A (zh) 2019-12-20
EP3038656A1 (en) 2016-07-06
TW201509422A (zh) 2015-03-16
EA034600B1 (ru) 2020-02-25
CA2921830A1 (en) 2015-03-05
US20240238329A9 (en) 2024-07-18
ES2893329T3 (es) 2022-02-08
US12285441B2 (en) 2025-04-29
MY180502A (en) 2020-11-30
AU2014314536B2 (en) 2019-11-07
AU2019268087A1 (en) 2019-12-12
EP3038656B1 (en) 2021-08-18
AU2017204619A1 (en) 2017-07-27
AU2019201691B2 (en) 2019-10-03
CA2921830C (en) 2022-03-08
JP2016529362A (ja) 2016-09-23
CN113893354A (zh) 2022-01-07
BR112016004357B1 (pt) 2022-09-27
AU2019201691A1 (en) 2019-04-04
US11229665B2 (en) 2022-01-25
WO2015031425A1 (en) 2015-03-05
EA201992517A3 (ru) 2020-05-31

Similar Documents

Publication Publication Date Title
EA201501166A1 (ru) Соединение гликозаминогликана, способ его получения и применение
CY1120429T1 (el) Παραγωγα κιναζολινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων
EA201492290A1 (ru) Составы и способы для вагинальной доставки антипрогестинов
EA201492052A1 (ru) Лечение миелосупрессии
EA201590622A1 (ru) Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
CO6640206A2 (es) Formulación farmaceútica de una solución acuosa de un bufer de ácido glutámico y un anticuerpo
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201491330A1 (ru) Терапевтически активные соединения и способы их использования
EA201390682A1 (ru) Спирооксиндольные антагонисты mdm2
EA201590855A1 (ru) Соединения пирролопиримидина как ингибиторы киназ
EA201300558A1 (ru) Соединения и способы для купирования боли
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
NZ720736A (en) Antibody drug conjugates (adcs) with kinesin spindel protein (ksp)
EA201391616A1 (ru) Применение тиазолидных соединений для предотвращения и лечения вирусных заболеваний, рака и заболеваний, вызванных внутриклеточными инфекциями
EA201590663A1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ
MD20150035A2 (ru) Ингибиторы тирозинкиназы Брутона
EA201692166A1 (ru) Гетероциклические ингибиторы глютаминазы
MX373851B (es) Métodos de administración de tratamiento con pirfenidona.
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
BR112014011744A2 (pt) formulação de ação sustentável da forma 2 de ciclosporina
EA201491702A1 (ru) Оптимизированные терапевтические агенты для подкожного введения
EA201501054A1 (ru) Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы